Discuss molecular pathways of solid tumors (glioma, melanoma, colon, lung, thyroid, etc.) and hematologic malignancy. |
|
|
|
|
|
Integrate molecular findings with morphology and clinical information. |
|
|
|
|
|
Demonstrate diagnostic, prognostic, and therapeutic property of each alteration in the gene detected. |
|
|
|
|
|
Consensus conference of the calling alterations with respect to a disease and the ethnicity of the patient. |
|
|
|
|
|
Identify available clinical trials for the specific alterations. |
|
|
|
|
|
Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics). |
|
|
|
|
|